Phenomenal Breakthrough: Scientists Discover New Drug That Fights Blood Cancer Without Toxic Side Effects Caused By Existing Medications
There is good news for those fighting leukaemia as scientists have made a fantastic breakthrough by discovering a drug that can combat blood cancer. The biggest advantage of the drug is that there are no side effects which were proved after 150 cancer patients were tested with the drug which was well tolerated. This makes the new drug far superior than existing ones that attack healthy cells in the process. The new drug can be better targeted and can treat chronic myeloid leukaemia that is more common in older people.
1Blood cancers have claimed the lives of approx. 56,770 people in the US alone in 2019
Today in the US alone one person dies of blood cancer every nine minutes.Leukemia is diagnosed 10 times more often in adults than children where almost 60,300 people are expected to be diagnosed with leukemia this year.Statistics for Leukemia, lymphoma and myeloma showed that the diseases were expected to cause the deaths of an estimated 56,770 people in the US in 2019. The new drug is like a miracle of sorts that when circulated commercially should bring down these numbers drastically.
2Present drugs have several side effects
In usual circumstances, the drugs used for myeloid leukaemia which are known as kinase inhibitors have side effects nausea, vomiting, diarrhoea and muscle pain. Over time these even stop being effective. When researchers tried the new drug asciminib, they found that though it works similarly, it was found to be more than effective and even well tolerated by patients.
3A phenomenal breakthrough
The researchers have declared it to be a phenomenal breakthrough in the treatment of chronic myeloid leukaemia CML that is more common in people over sixty. The drug offers a new option especially in patients who have exhausted their options of existing drugs. The 150 patient trials showed positive results. It was found that Asciminib did not show any toxic effects and worked effectively in all patients.
4What does it do?
Asciminib which belongs to the class of drugs called Kinase inhibitors inhibits the blood cancer by shutting down specific kinases, the enzymes that cause cancer. In the nineties, doctors worldwide have expressed huge hope and praised the creation of the world’s first tyrosine kinase inhibitor TKI called imatinib. They felt it had changed the lives of patients with the disease because it had the power to turn the disease from a death sentence to something that could be managed to allow people to live a longer and complete life.